CELLINK publishes prospectus and new financial information due to admission to trading of shares of series B on Nasdaq Stockholm
At the extraordinary general meeting of CELLINK AB (publ) (“CELLINK” or the “Company”) on September 11, 2020, a directed share issue resolved by the board of directors of 1,625,000 shares of series B to a Swedish institutional investor approached in advance was approved. Due to this, the board of directors of CELLINK has prepared a prospectus for admission to trading of the shares, which has today been approved and registered by the Swedish Financial Supervisory Authority (“SFSA”). The prospectus contains, due to regulatory requirements, updated financial information as of July 31, 2020,